Adherence in Hemophilia A
Launch Date:
November 17, 2020
Expiration Date:
November 17, 2021
primary audience:
Hematologists, Hematology nurse practitioners, Hematology nurses, Hematology physician assistants, Hematology/oncology fellows
Relevant Terms:
Adherence, Factor replacement, Hemophilia, Hemophilia a. hematology, Immune tolerance induction, Inhibitors
Jordan A. Shavit, MD, PhD
Dr Jordan A. Shavit is Associate Professor of Pediatrics at the University of Michigan and a pediatric hematologist/oncologist at the CS Mott Children’s Hospital in Ann Arbor, Michigan. He earned his medical and doctorate degrees from Northwestern University School of Medicine in Chicago, Illinois. He then completed a residency in pediatrics and a fellowship in pediatric hematology/oncology at the University of Michigan Health System. He is board certified in pediatric hematology-oncology.
Dr Shavit specializes in the care of pediatric patients with hemophilia, von Willebrand disease and other bleeding disorders, thrombotic disorders, and thrombophilia. He is a member of multiple societies, including the American Society of Hematology, International Society on Thrombosis and Haemostasis, Hemostasis and Thrombosis Research Society, American Society for Clinical Investigation, and American Pediatric Society.
Doris V. Quon, MD, PhD
Dr Doris V. Quon is Medical Director for the Orthopaedic Hemophilia Treatment Center (OHTC) in Los Angeles, California, and a medical oncologist for the Sarcoma Oncology Center in Santa Monica, California. She has an active role in coordinating the federally funded Region IX hemophilia activities for the OHTC and is Medical Advisor for the Hemophilia Foundation of Southern California in Pasadena. She earned her medical degree from the University of California, Los Angeles (UCLA) David Geffen School of Medicine. She then completed a residency in internal medicine, a clinical fellowship in hematology/oncology, and a research fellowship in hematology/oncology at the UCLA Medical Center.
Dr Quon cares for individuals with bleeding disorders and the complications of those disorders at the OHTC, the largest treatment center for individuals 14 years and older in Southern California with bleeding disorders. Her research in hemophilia has led to 40 publications in peer-reviewed journals such as Haemophilia, Blood Advances, the European Journal of Haematology, and the Journal of Thrombosis and Haemostasis. She is a member of multiple societies, including the International Society on Thrombosis and Haemostasis, American Society of Hematology, American Society of Clinical Oncology, National Hemophilia Foundation, and the Hemostasis and Thrombosis Research Society.
This educational activity is jointly provided by the American Academy of CME and Spire Learning.
This activity is supported by an educational grant from Genentech, Inc.
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Spire Learning. American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians: American Academy of CME, Inc., designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NPs/Nurses: American Academy of CME, Inc., designates this educational activity for 0.25 ANCC contact hours (0.25 pharmacotherapeutic contact hours).
There is no fee to participate in this program. In order to receive CME/CE credit, you must complete:
• Pretest
• Activity
• Posttest
• Activity Evaluation
Your certificate can be printed immediately.
CONFLICT OF INTEREST STATEMENT
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
EDUCATIONAL PLANNING COMMITTEE
Co-Chairs
Doris V. Quon, MD, PhD
Medical Oncologist, Sarcoma Oncology Center
Medical Advisor, Hemophilia Foundation of Southern California
Medical Director, Orthopaedic Hemophilia Treatment Center
Advisory Board – for marketing purposes: Bayer Corporation; Genentech, Inc; Novo Nordisk
Advisory Board – for scientific information: Bayer Corporation; Genentech, Inc; Novo Nordisk; uniQure
Consultant – for clinical trial design: Genentech, Inc
Promotional Speaker’s Bureau: Bioverativ/Sanofi; Genentech, Inc; Novo Nordisk; Shire/Takeda
Jordan A. Shavit, MD, PhD
Associate Professor of Pediatrics
Division of Pediatric Hematology/Oncology
University of Michigan Medical School
CS Mott Children’s Hospital
No relevant financial relationships with any commercial interests.
American Academy of CME, Inc.
John Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD: No relevant financial relationships with any commercial interests.
Spire Learning
Ashton Beggs, PharmD, BCACP, and Shirley Jones, MBA: No relevant financial relationships with any commercial interests.
Jeanne Prater: Employee (spouse): Novo Nordisk Inc; Shareholder (spouse): Johnson & Johnson.
Reviewer
Brenda Riske, RN, MSN, MBA, MPA: No relevant financial relationships with any commercial interests.
Nihal Bakeer, MD: Grant/Research Support: Genentech, Inc
Eric Kraut, MD: Advisory Board ‒ for scientific information: Alnylam Pharmaceuticals; uniQure
Magdalena Lewandowska, MD, Angeli Rampersad, MD, and Beverly Schaefer, MD: No relevant financial relationships with any commercial interests.
This educational activity may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.
DISCLAIMER
The opinions expressed in this educational activity do not represent those of the Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information. Spire Learning, LLC and American Academy of CME, Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
PRIVACY STATEMENT
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
COPYRIGHT STATEMENT
Copyright © 2020 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or program may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and American Academy of CME, Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or program, including any claims related to the products, drugs, or services mentioned herein.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. |
Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above
|
Related Courses
Management of Inhibitors in Hemophilia A
This educational activity is jointly provided by the American Academy of CME and Spire Learning. T...
Launches:
Nov 17, 2020
Expires:
Nov 17, 2021
Personalizing Hemophilia A Prophylaxis Regimens
This educational activity is jointly provided by the American Academy of CME and Spire Learning. T...
Launches:
Nov 17, 2020
Expires:
Nov 17, 2021
